UNITED STATES SECURITIES AND EXCHANGE COMMISSION From the transition period from to . Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 Delaware 65-1311552 (State or other jurisdiction of i ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 65-1311552 (State or other jurisdiction of incorp ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q1 2023 Earnings Conference Call May 3, 2023 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Ed Dulac - Chief Financial Officer Wayne Chu - Chief Medical Officer Bob Valamehr - Chief Research and Development Officer Conference Call Participants Tazeen Ahmad - Bank of America Mara Goldstein - Mizuho Daina Graybosch - SVB Securities Andrea Tan - Goldman Sachs Matthew Biegler - Oppenheimer Operator Welcome to the Fate Therapeutics Firs ...

Financial Performance - The company has incurred net losses since inception, with significant losses attributed to research and development costs and general administrative expenses [125]. - The company has not generated any revenues from therapeutic product sales or royalties to date, relying instead on collaboration agreements and government grants [128]. - The company anticipates continued operating losses for the foreseeable future as it invests in research and development activities [125]. - As of March 31, 2023, the company had an accumulated deficit of $1.1 billion and anticipates continued net losses for the foreseeable future [154]. - The company expects to incur losses for the foreseeable future as it continues research and development activities, with potential increases in losses anticipated [177]. Collaboration Agreements - Collaboration revenue for the three months ended March 31, 2023, was $52.3 million under the Janssen Agreement, compared to $15.9 million for the same period in 2022 [132]. - The company recognized $6.7 million of collaboration revenue under the Ono Agreement for the three months ended March 31, 2023, up from $2.5 million in the same period in 2022 [139]. - The company has entered into multiple collaboration agreements, including a $100 million agreement with Janssen, which included a $50 million upfront cash payment [129]. - Collaboration revenue increased to $58.98 million for the three months ended March 31, 2023, compared to $18.41 million for the same period in 2022, reflecting a $40.57 million increase attributed to the recognition of deferred revenue from the Janssen contract termination [150]. - Under the Ono Agreement, the company received an upfront payment of $10 million and is eligible for up to $40 million in additional payments based on preclinical milestones [160]. - The company is entitled to receive up to $843.0 million in milestone payments for each candidate under the Ono Agreement, with $10.0 million received in December 2020 and $12.5 million in November 2022 [166]. Research and Development - The company plans to increase research and development expenses to support ongoing clinical trials and the development of its iPSC product platform [141]. - The company has discontinued its FT516, FT596, FT538, and FT536 NK cell programs to focus on more innovative projects [123]. - The company has a research collaboration with the University of Minnesota and Memorial Sloan Kettering Cancer Center to develop engineered NK and T-cell cancer immunotherapies [120]. - Research and development expenses decreased to $65.63 million for the three months ended March 31, 2023, down from $72.14 million in the same period in 2022, a reduction of $6.51 million [151]. Expenses and Cash Flow - General and administrative expenses rose to $21.94 million for the three months ended March 31, 2023, compared to $20.74 million in the same period in 2022, an increase of $1.20 million primarily due to higher patent and legal expenses [151]. - Cash used in operating activities decreased to $28.9 million for the three months ended March 31, 2023, compared to $64.6 million for the same period in 2022, primarily due to a decrease in net loss [155]. - The company incurred $17.1 million in sublicense fees related to the Janssen Agreement, with $15.6 million paid as of March 31, 2023 [159]. - The company reversed the liability associated with the CIRM Award, recording it as other income during the three months ended March 31, 2023, following the discontinuation of the FT516 program [147]. - Other income increased to $9.71 million for the three months ended March 31, 2023, compared to $8.78 million in the same period in 2022, including $4.0 million from the CIRM Award [152]. Capital and Funding - The company may require additional capital for research and development and may seek funds sooner than expected due to various risks, including inflation and global economic conditions [179]. - The company has entered into a sales agreement for an at-the-market offering program, allowing it to sell up to $350.0 million in common stock [176]. - The company received $100 million from the Janssen Agreement, which included a $50 million upfront cash payment and a $50 million equity investment [156]. Market and Economic Factors - Inflationary factors may adversely affect the company's operating results, although no material impact has been observed to date [185]. - The company is exposed to interest rate risk, but a 10% change in market interest rates would not have a material impact on its financial condition [186]. - The company has no material contractual obligations not fully recorded or disclosed in its financial statements [184].

Fate Therapeutics, Inc. (NASDAQ:FATE) Q4 2022 Earnings Conference Call February 28, 2023 5:00 PM ET Company Participants Scott Wolchko - President and Chief Executive Officer Wayne Chu - Chief Medical Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research and Development Officer Conference Call Participants Carly Kenselaar - Citi Daina Graybosch - SVB Securities Tazeen Ahmad - Bank of America Andrea Tan - Goldman Sachs Robyn Karnauskas - Truist Mara Goldstein - Mizuho Matthew Biegler - Opp ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number 001-36076 FATE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of ...

Better Cells For Better Therapies™ | --- | --- | |----------------------------------------------------------------------------------------------------------------------|-------| | | | | Programmed Cellular Immunotherapies | | | Transforming the Treatment of Cancer with Off-the-shelf, Multiplexed-engineered, iPSC-derived Cellular Immunotherapy | | | November 2022 | | - Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Re ...

Fate Therapeutics, Inc. (NASDAQ:FATE) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President & Chief Executive Officer Ed Dulac - Chief Financial Officer Bob Valamehr - Chief Research & Development Officer Conference Call Participants Tazeen Ahmad - Bank of America Michael Yee - Jefferies Tyler Van Buren - Cowen Yigal Nochomovitz - Citigroup Michael Schmidt - Guggenheim Securities Daina Graybosch - SVB Securities Peter Lawson - Barclays Gil Blum - Needham ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Title of each class Trading symbol(s) Name of each exchange on which registered Common Stock FATE Nasdaq Global Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT OF 1934 From the transition period from to . Commission File Number 001-36076 (Exact name o ...

Fate Therapeutics Inc. (NASDAQ:FATE) Q2 2022 Earnings Conference Call August 3, 2022 5:00 PM ET Company Participants Scott Wolchko - President and CEO Ed Dulac - CFO Yu-Waye Chu - Chief Medical Officer Conference Call Participants Tazeen Ahmad - Bank of America Kelsey Goodwin - Guggenheim Securities Tyler Van Buren - Cowen Ashiq Mubarack - Citigroup Michael Yee - Jefferies James Shin - Abbott Matt Biegler - Oppenheimer Daina Graybosch - SVB Securities Robyn Kay Karnauskas - Truist Securities Operator Welcom ...